Yingkang life: it is expected to lose 300 million yuan to 370 million yuan in 2021
According to Yingkang life's announcement, it is expected to lose 300 million yuan to 370 million yuan in 2021 and make a profit of 150 million yuan in the same period of last year (after reorganization). It is expected that about 450 million yuan of impairment provision will be made for the goodwill formed by the acquisition of masip this year.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 18, 2022 06:30 PM
Briefing Apr 27, 2022 05:16 PM
Beautiful Ecology: the net profit in the first quarter increased by 24.92% to 1.9755 million yuan
Briefing Apr 25, 2022 09:45 AM
The coal sector fell sharply at the opening, and Shanghai Energy fell by the limit
Healthcare
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Healthcare · Analysis
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM
Digital Zhengtong: new orders signed in the first two months increased by more than 60% year-on-year
Briefing Mar 14, 2022 07:48 AM
· Healthcare
Defining key tasks and accelerating the construction of new urbanization
See more
Read next
Insight
In-depth
Insight
In-depth